Ecofibre’s EOF-Bio Eyes Phase 2a Clinical Trials

Ecofibre Ltd. (AU:EOF) has released an update.

Ecofibre Ltd. announces progress with its subsidiary EOF-Bio Inc., reporting upcoming Phase 2a clinical trials for a new cannabinoid-based drug targeting Endometriosis Associated Pain (EAP), intended to improve health and quality of life. The company is also enhancing its strategic partnerships for drug manufacturing and has strengthened its board with a new director experienced in botanical drug development. Despite facing ongoing litigation, EOF-Bio is advancing with institutional investor engagement for its capital raise and has expanded its intellectual property portfolio with rights to eight issued patents.

For further insights into AU:EOF stock, check out TipRanks’ Stock Analysis page.